Company Number: 13266138

Analysis Date: 2025-07-29 14:04 UTC

1. Industry Classification
   ENNOGEN IP LTD operates primarily in the pharmaceutical sector, with SIC codes 46460 (Wholesale of pharmaceutical goods) and 21100 (Manufacture of basic pharmaceutical products). This sector is characterised by high regulatory scrutiny, significant investment in R&D, intellectual property management, and supply chain complexity. The wholesale segment focuses on distribution efficiency and regulatory compliance, while manufacturing of basic pharmaceuticals demands robust quality control and capital-intensive production facilities.

2. Relative Performance
   ENNOGEN IP LTD is classified as a small private limited company, though its financials show substantial intangible assets (£8.645 million) and shareholders’ funds (£8.95 million) as of the 2022 year-end. This is notable given the company’s account size category, indicating strong capital backing and significant investment in intangible assets, likely intellectual property or product formulations. The company reported a modest profit before tax (£49k) but had a slight loss after tax (£46k) due to amortisation and tax charges, reflecting typical early-stage pharmaceutical enterprises investing heavily in IP amortisation. Compared to typical small pharmaceutical wholesalers or manufacturers, ENNOGEN IP LTD’s asset base is significant, suggesting it is more capital-intensive or IP-heavy than many peers in the small category.

3. Sector Trends Impact
   The pharmaceutical industry is currently influenced by several trends: increased demand for innovative medicines, supply chain disruptions, and a push for cost efficiencies in distribution. Additionally, regulatory changes such as Brexit-related adjustments to UK pharmaceutical regulations and ongoing global supply chain challenges affect wholesale operations. ENNOGEN IP LTD, with its dual focus on manufacturing and wholesale, is positioned to benefit from growing demand for pharmaceutical products but must navigate cost pressures and compliance complexity. The emphasis on intangible assets indicates a strategic focus on proprietary products or formulations, aligning with sector trends prioritising innovation and patent-protected products.

4. Competitive Positioning
   ENNOGEN IP LTD appears to be a niche player within the broader pharmaceutical sector, leveraging intangible assets likely related to intellectual property or product development. Its strong equity position and sizeable intangible assets set it apart from typical small-scale wholesalers, which often have lower capital intensity and asset bases. However, the company’s modest profit and loss position indicates it is still in a growth or investment phase, which is common for companies developing proprietary pharmaceutical products. Its competitive strengths lie in its investment in IP and integration of manufacturing and wholesale functions, which may allow greater control over product quality and supply chain. Constraints include its relatively small turnover and current low profitability, typical of early-stage pharmaceutical businesses competing against larger, entrenched manufacturers and distributors.